Imlygic Injection, Suspension
Product Images NDC 55513-078

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Imlygic (NDC 55513-078). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Injection Administration For Cutaneous Lesions (Imlygic 01)

An instructional illustration showing two syringes injecting a substance directly into a lesion or tumor on the skin, demonstrating intra-lesional administration technique likely related to Imlygic (talimogene laherparepvec) injection, suspension.*

FDA Label Image

Figure 2: Injection Administration For Subcutaneous Lesions (Imlygic 02)

An instructional illustration depicting two syringes injecting a substance directly into a raised lesion or tumor on the skin, demonstrating the intra-lesional administration technique likely associated with the Imlygic injection suspension.*

FDA Label Image

Figure 3: Injection Administration For Nodal Lesions (Imlygic 03)

An instructional or anatomical figure depicting a cross-sectional view of an injection into a lesion. The diagram shows the targeted injection path of Imlygic (talimogene laherparepvec) suspension intended for intralesional administration.*

FDA Label Image

Figure 4: Single-use Vial Permanently Inserted Into A Clear Copolyester Plastic Sleeve (Imlygic 04)

Packaging label for Imlygic Injection, Suspension, an intralesional human prescription drug containing talimogene laherparepvec. The illustration shows a carton with two vials inside, designed for injectable suspension. The product is labeled by Amgen Inc.*

FDA Label Image

Figure 5: Single-use Vial Without A Clear Plastic Sleeve (Imlygic 05)

The image shows a vial of Imlygic (talimogene laherparepvec) injection, suspension for intralesional use. The vial has a white cap and a blank label, without visible text or strength indication. The product is labeled by Amgen Inc.*

FDA Label Image

Imlygic 06

Imlygic (talimogene laherparepvec) 10^6 PFU/mL injection, suspension, provided as a single-use vial. The label includes dosage instructions emphasizing single vial use and disposal of unused portions, storage conditions from -90°C to -70°C (-130°F to -94°F), and the requirement for intralesional injection only. The label lists inactive ingredients and requires following enclosed medication guide and package insert for full prescribing information. Manufactured by Amgen Inc.*

FDA Label Image

Principal Display Panelstore At -70⁰c To -90⁰c (-94⁰f To -130⁰f)talimogene Laherparepvec106 Pfu/ml106 Pfu/mlfor Intralesional Injection Onlybiovex, Inc., A Subsidiary Of Amgen Inc.,one Amgen Center Drive, Thousand Oaks, California 91320-1799rx Onlylot:exp.: (Imlygic 07)

Imlygic 10^8 PFU/mL single use vial injection label by Amgen Inc. The label includes the proprietary name Imlygic and generic name talimogene laherparepvec, indicating a suspension for intralesional injection. It details the vial contents, storage instructions (-90°C to -70°C), usage directions emphasizing single use and no dilution, and a warning for healthcare providers about enclosing the Medication Guide. The label also lists inactive ingredients and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.